BOSTON, May 11, 2021 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of novel therapies for diseases involving mitochondrial
dysfunction, today announced that it will report first quarter
2021 financial results on Tuesday, May 18,
2021, before the market opens.
Management will host a conference call at 8:30 am
ET that day to discuss the financial results and provide a
general business update. The call can be accessed by dialing
(877)-407-0989 (domestic) or (201)-389-0921 (international) and
referencing conference ID 13719019. A live audio webcast of the
event can be accessed by visiting the Investors & News section
of Stealth's Investor
website, https://investor.stealthbt.com/. A replay of the
webcast will be archived on Stealth's website for 30 days following
the event.
About Stealth
We are a clinical-stage biotechnology company focused on the
discovery, development, and commercialization of novel therapies
for diseases involving mitochondrial dysfunction. Mitochondria,
found in nearly every cell in the body, are the body's main source
of energy production and are critical for normal organ function.
Dysfunctional mitochondria characterize a number of rare genetic
diseases and are involved in many common age-related diseases,
typically involving organ systems with high energy demands such as
the heart, the eye, and the brain. We believe our lead product
candidate, elamipretide, has the potential to treat both rare
metabolic cardiomyopathies, such as Barth, Duchenne muscular
dystrophy and Friedreich's ataxia, rare mitochondrial diseases
entailing nuclear DNA mutations, as well as ophthalmic diseases
entailing mitochondrial dysfunction, such as dry age-related
macular degeneration and Leber's hereditary optic neuropathy. We
are evaluating our second-generation clinical-stage candidate,
SBT-272, and our new series of small molecules, SBT-550, for rare
neurological disease indications following promising preclinical
data. We have optimized our discovery platform to identify novel
mitochondria-targeted compounds which may be nominated as
therapeutic product candidates or utilized as mitochondria-targeted
vectors to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-report-first-quarter-financial-results-on-tuesday-may-18-2021-301289064.html
SOURCE Stealth BioTherapeutics Inc.